Non Small Cell Lung Cancer (NSCLC)

Stage III Met - IV 2nd Line - Immunotherapy

No Prior Therapy With PD-1/PD-L1

LUN0085
Phase II
Pembrolizumab in Metastatic Non-Squamous NSCLC Examining Circulating Tumor DNA Levels
Pl: Neal Stanford
1st Priority

LUN0093
Phase II
NKTR-214 + Nivolumab in Select Locally Advanced or Metastatic Solid Tumor Malignancies
Pl: Neal Nektar
2nd Priority

VAR0170
Phase Ib
Cabozantinib (XL184) in Combo w/Atezolizumab in Locally Advanced or Metastatic Solid Tumors
Pl: Srinivas Pending
3rd Priority

LUN0088
Phase II
Radical-Dose RT with Anti-PD-1/ Anti-PD-L1 Immunotherapy in Non-Small Cell Lung Cancer
Pl: Gensheimer Stanford
1st Priority

On anti PD-1/ anti PD-L1 with response, stable disease or modest progression

VAR0170
Phase Ib
Cabozantinib (XL184) in Combo w/Atezolizumab in Locally Advanced or Metastatic Solid Tumors
Pl: Srinivas Pending

VAR0170
ECOGS1400
Phase II/III Biomarker in Second Line Therapy of Squamous Cell Lung Cancer (Screening Step)
Pl: Wakelee
2nd Priority

Failed Therapy PD-L1

LUN0107
Phase Ib/II
Grapiprant +/- Pembrolizumab in Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma
Pl: Wakelee Aris Therapeutics
2nd Priority

KEY
- Pending
- Open for Enrollment
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu